NEW YORK (Reuters) - An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it becoming the first approved therapeutic …
Its stock has essentially doubled from an intraday low in the ... and the company had yet to recognize the closing of the Dendreon sale for $819.9 million to China's Sanpower Group. Additionally, Valeant was able to find a buyer for …
issued information on revenue and EBITDA losses related to three divestitures (iNova, Dendreon, and Obagi), which implies that ... negative to our Underperform thesis in the short-term. The stock has rallied on debt repayment news but …
In a nano-second, Dendreon went from obscurity to savior. Investors holding Dendreon stock suddenly found themselves instant millionaires. Dendreon is an excellent example of how a stock can shock the market, or what I call a "mini …
What the common stockholder needs to understand here is that this could represent a total wipeout of the common stock value. Dendreon said that it has reached agreements on the terms of a financial restructuring with certain holders of its …
Investors in Dendreon Corp (NASD: DNDN) saw new options become available today, for the August 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new August …
Dendreon continued to watch its stock decline Wednesday, a day after the Seattle company announced it might not …
DNDN) had announced on October 7 that its third quarter operation results will be declared on November 12. Investors in the stock, which has total outstanding shares of 151 million, would be hoping that the 3Q results would be able to rally …
It’s been almost a year since we covered Dendreon announcing its successful Phase III clinical trials for its prostate treatment Provenge. Now, the Seattle based company is continuing its work of getting Provenge, also known as …
NEW YORK, April 28 (Reuters) - Dendreon Corp's DNDN.O shares swung wildly on Tuesday, at one time rising 16 percent and then subsequently sliding more than 60 percent as investors braced for data from a study involving a …